-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们将目标股价下调36加元至102加元，市盈率为11.5倍（基于2026财年9月公布的每股收益预期），低于CGI三年平均水平（约18倍），主要原因是宏观经济不确定性和美国联邦风险。我们将2026财年每股收益预期下调0.02加元至8.88加元，并将2027财年每股收益预期下调0.12加元至9.40加元。我们担心第二季度销售额持续放缓（不计汇率影响增长1.6%，环比下降180个基点，同比下降170个基点）反映的是结构性压力，而不仅仅是暂时性问题。 第二季度订单量同比下降4%，过去12个月的订单出货比为108.4%（同比下降220个基点），这些都预示着风险，因为客户持续推迟支出决策。我们注意到，尽管美国联邦业务的订单表现强劲（过去12个月的订单出货比为110.9%），但订单量仍然出现下滑。CGI预计第三季度美国联邦业务的有机销售增长将恢复，但这一预期存在不确定性，而且我们认为，欧洲市场的疲软可能会掩盖这一增长。公司缺乏正式的业绩指引也加剧了我们的不确定性。尽管如此，如果CGI能够实现目标，那么低于历史水平的估值以及美国联邦业务第三季度有机销售增长的预期，将带来短期上涨空间。
Related Articles
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Sofi Technologies, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $4 to $18, applying a P/E of 17.8x our 2028 EPS view vs. SOFI's 71.2x three-year historical forward P/E average. We keep our 2026 EPS estimate at $0.58, 2027's at $0.81, and 2028's at $1.01. We expect robust member and product growth, fueled by key initiatives like crypto and the SoFi Plus relaunch, to support sustained double-digit revenue expansion. The relaunched SoFi Plus introduces a paid subscription to fuel cross-selling, while the crypto initiative leverages its unique, bank-issued stablecoin to become a core infrastructure provider for digital assets.However, this outlook is reflected in a rich valuation that leaves minimal room for execution missteps. We remain neutral, as a sustained high-rate environment could stress consumers and impact credit performance, a key risk given the company's large personal loan portfolio. Management's decision to not raise full-year guidance, despite a strong quarter, balances strategic investments against macroeconomic uncertainties.
$SOFI
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Tenet Healthcare
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $200 from $260, 11.4x our 2026 EPS estimate (up to $17.56 from $17.33; 2027 estimate up to $18.00 from $17.85), a discount to the company's three-year historical forward average of 12.9x. We think THC's valuation balances recent deleveraging efforts and a stronger margin profile than in previous years against policy headwinds, including cuts to Medicaid coverage under the OBBBA legislation and the recent expiration of ACA enhanced premium tax credits, which increases risk of higher uncompensated care. Same-facility ACA exchange admissions fell 10% Y/Y in Q1, and THC guides for a 20% reduction in ACA exchange patient volumes for 2026 and anticipates a negative $250 million impact on adjusted EBITDA. While we expect THC to revisit annual guidance in Q2 earnings, at which point a clearer picture of the insurance coverage landscape is likely, we look favorably on the company maintaining its annual inpatient/outpatient volume guidance for now.
$THC
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of Sanmina Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $87 to $250, 19.3x our FY 27 EPS estimate. We increase our FY 26 EPS estimate by $1.16 to $11.23 and raise FY 27's by $1.28 to $12.95. SANM noted strong growth in revenue, particularly in the Communication Networks & Cloud AI Infrastructure segment, which saw significant year-over-year expansion. This growth was attributed to strong demand in areas such as accelerated compute, general-purpose compute, and storage, as well as contributions from both Core Sanmina and the ZT Systems business. Positive momentum was observed in other end markets like Industrial & Energy, where the business is expected to accelerate growth in the second half of the year, particularly in power generation, distribution, and semiconductor capital equipment. There was an emphasis on the company being well prepared for future growth, supported by a diversified customer base, expansion into new programs, and a global manufacturing footprint positioned for anticipated demand in 2027 and 2028.
$SANM